NFKB1 and acute myeloid leukemia: Furthermore, the AML cells were treated with FAK (PF-573228, 20 nM, 24 h), Akt (AKT-IN-1, 5.21 μM, 24 h), and NF-κB inhibitors (JSH-23, 35.5 μM, 24 h)(Figure 4c).